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Abstract
Patients with CKD have abnormal vascular remodeling that is a risk factor for cardiovascular disease. MicroRNAs (miRNAs)
control mRNA expression intracellularly and are secreted into the circulation; three miRNAs (miR-125b, miR-145 and miR-
155) are known to alter vascular smooth muscle cell (VSMC) proliferation and differentiation. We measured these vascular
miRNAs in blood from 90 patients with CKD and found decreased circulating levels with progressive loss of eGFR by
multivariate analyses. Expression of these vascular miRNAs miR-125b, miR-145, and miR-155 was decreased in the thoracic
aorta in CKD rats compared to normal rats, with concordant changes in target genes of RUNX2, angiotensin II type I
receptor (AT1R), and myocardin. Furthermore, the expression of miR-155 was negatively correlated with the quantity of
calcification in the aorta, a process known to be preceded by vascular de-differentiation in these animals. We then examined
the mechanisms of miRNA regulation in primary VSMC and found decreased expression of miR-125b, 145, and 155 in VSMC
from rats with CKD compared to normal littermates but no alteration in DROSHA or DICER, indicating that the low levels of
expression is not due to altered intracellular processing. Finally, overexpression of miR-155 in VSMC from CKD rats inhibited
AT1R expression and decreased cellular proliferation supporting a direct effect of miR-155 on VSMC. In conclusion, we have
found ex vivo and in vitro evidence for decreased expression of these vascular miRNA in CKD, suggesting that alterations in
miRNAs may lead to the synthetic state of VSMC found in CKD. The decreased levels in the circulation may reflect decreased
vascular release but more studies are needed to confirm this relationship.
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Introduction
MicroRNAs (miRNAs) are small (approximately 22 nucleotide),
non-coding RNAs that function to regulate messenger RNAs
(mRNAs) post-transcriptionally by degrading or repressing
mRNA. miRNAs play a critical function during development
through effects on cell proliferation, differentiation, and apoptosis
[1,2]. In the adult, abnormalities in miRNA have been identified
in multiple disease states, including malignancies, inflammatory
diseases, and cardiovascular diseases [1,3]. The miRNA are
further processed in the nucleus through activity of DROSHA, an
RNAse III, into precursor miRNA that are transported into the
cytoplasm. There they are cleaved by DICER to generate miRNA
that are incorporated into the RNA-induced silencing complex
(RISC) to form a RISC-miRNA complex that represses mRNA
transcription or enhances mRNA degradation[3]. It is estimated
that there are up to 1000 human miRNA, and that the majority of
mRNA are potential targets of miRNA. Furthermore, each
miRNA may affect multiple mRNA, and each mRNA may have
multiple miRNA regulating its transcriptional activity [4,5]. The
miRNA are resistant to degradation, and in addition to their
cellular effects, are released into the circulation and thus may also
serve as circulating biomarkers[5,6]. For example, in non-CKD
patients with cardiovascular disease, miR-145 and miR-155 were
found to be lower in patients with coronary artery disease than in
those without [7].
Chronic kidney disease (CKD) is a known cardiovascular risk
factor, and most patients with CKD die of cardiovascular disease
before reaching the need for dialysis[8]. Once on dialysis,
cardiovascular disease (CVD) accounts for 30% of hospitalizations
and 50% of the mortality[9]. CKD is associated with a high
prevalence of hypertension and diabetes, explaining some of this
increased risk. However, non-traditional risk factors such as
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-
MBD)[10–12] and inflammation[13,14] have also been strongly
associated with morbidity and mortality in CKD. Abnormal gene
expression and cellular function due to derangements in miRNA
expression may be one, as yet, unexplored mechanism for the
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pathogenesis of increased CVD risk in CKD. Therefore, in the
present study we evaluated three ‘‘vascular’’ miRNAs that are
known to be expressed in the artery and involved in vascular
smooth muscle cell (VSMC) differentiation (miR-145 and
155)[2,15,16], inflammatory vascular disease (miR-155)[17–19],
abnormalities in the angiotensin pathway (miR-155) [20–22] and
arterial calcification (miR-125b)[23,24] in patients with CKD. All
of these vascular miRNAs have been shown in animal models to
regulate VSMC de-differentiation, resulting in a more synthetic/
proliferative phenotype that pre-disposes to altered remodeling
response to stress. We assessed the circulating levels in CKD
patients, the tissue expression in arteries ex vivo from CKD rats
compared to normal animals, and the regulation of expression in
cultured VSMC from CKD rats.
Materials and Methods
Human study
Ethics Statement. The study was approved by the IUPUI
Institutional Review Board. All participants gave written informed
consent with documentation to that effect in accordance with
IUPUI standard operating procedures. (IRB#0707-04 and
IRB#0011-48).
To determine if CKD affects the expression of circulating miR-
125b, miR-145 and miR-155, we analyzed the expression in
stored sera from 90 stage 3–4 CKD patients who had participated
in a previous study and consented for future use of their blood
samples. Inclusion criteria were stage 3–4 CKD (defined as
estimated glomerular filtration rate [eGFR] calculated from 4-
parameter MDRD equation ranged by 15 – 59 ml/min/1.73 m2),
hemoglobin .10 g/dL, age .18 years, no evidence of active
infection or inflammatory process, and not hospitalized within the
previous 30 days. Subjects were determined to have atherosclerotic
vascular disease (coronary artery disease, cerebrovascular accident,
or peripheral vascular surgery/amputation) by self- report at the
time of sample collection and/or retrospective chart review. The
presence of left ventricular hypertrophy (LVH) was documented
from echocardiographic reports performed within 2 years before
or after the sample collection. The sera had been frozen at –80uC
for an average of 25.366.8 months in aliquots with no previous
freeze-thaws. To confirm that the storage had no effect on
expression and to compare more diverse levels of kidney function,
we also prospectively collected sera from 10 stage 3 and 4 CKD
patients, 10 hemodialysis patients and 8 healthy volunteers and
analyzed the samples within one month.
Animal models and tissue harvest
To confirm that these vascular miRNA may be indicative of
underlying tissue abnormalities, we utilized existing tissue samples
from prior experiments with the Han:SPRD Cy/+IU rat with
polycystic kidney disease (ADPKD) [25]. This is an autosomal
dominant condition, such that at birth, 1/4 of the animals are
normal (+/+), 1/2 are heterozygotes (Cy/+), and 1/4 are affected
homozygotes (Cy/Cy). Homozygous Cy/Cy rats develop mas-
sively enlarged kidneys and severe azotemia, and normally die by 4
weeks of age. The male Cy/+ rat develops a persistent azotemia
starting at about 10 weeks of age, which progresses to terminal
uremia by about 40 weeks, with spontaneous and slow develop-
ment of all three manifestations of CKD-MBD: biochemical
abnormalities, extraskeletal calcification, and abnormal bone[25].
Weaned rats were housed in open top, shoebox cages, and had
free access to tap water and standard chow until they were 24
weeks old when they were switched from a standard pellet rat
chow to a powdered diet of 18% casein-based protein, 0.7%
phosphorus, 0.7% calcium, 5% fat (Harlan Teklan TD.04539).
The animals (Cy/+ rat and normal littermate +/+, hereafter called
CKD and Normal rat) were sacrificed at 35 weeks with
pentobarbital (50 mg/kg intraperitoneally) and thoracic aortas
were weighed and collected and stored at –80uC for RNA
isolation. To quantify aorta calcification, proximal segments of
thoracic aortas from normal or CKD animals were snap frozen.
The aorta section was then weighed and incubated in 0.6N HCl
for 48 hrs. The samples (n = 8 per group) were then homogenized,
centrifuged, and the supernatant analyzed for calcium using the o-
cresolphthalein complex one method (Calcium kit; Pointe
Scientific) as previously published[26].
All procedures were reviewed and approved by the Indiana
University School of Medicine Institutional Animal Care and Use
Committee.
RNA isolation and quantification
Total RNA from normal or CKD rat thoracic aorta was isolated
using miRNeasy Mini Kit (Qiagen) according to the manufactur-
er’s instruction. Similarly, total RNA from human serum (400 ul)
or cell lysate was isolated using the same kit. Total RNA was
eluted from the column in RNase-free water and stored at –80uC.
Quantification of miRNA was performed at the Center for
Genetics in Indiana University School of Medicine using Agilent
2100 Bioanalyzer Small RNA kit.
Cell culture
To determine potential mechanisms for our tissue findings, rat
vascular smooth muscle cells (RVSMC) were isolated from
descending thoracic aorta of the Han:SPRD Cy/+IU (CKD) or
normal rats by the explant method as previously described [27].
Cells were used at passage 3–5 and grown in Dulbecco’s Modified
Eagle’s Medium (DMEM; Sigma, St. Louis, Mo., USA) containing
10% fetal bovine calf serum (FBS) until confluent at which time
they were cultured in DMEM with 15% FBS, 10 mM of sodium
pyruvate, 100 mM of insulin, and 50 ug/ml of ascorbic acid for
various times. Cell lysates were homogenized and collected in
QIAzol Lysis Reagent (Qiagen) according to manufacturer’s
protocol and kept at -80uC until RNA isolation.
Real time PCR
miRNA expression was determined by real time PCR using
TaqMan miRNA assays (Applied Biosystems, Foster City, CA).
Forty ng of total RNA were used for reverse transcription to
synthesize complementary DNA using TaqMan miRNA-specific
primers and the Taq reverse transcription kit (Applied Biosystems,
Foster City, CA). Target-specific PCR primers (miR-125b, miR-
145, miR-155 and miR-210) were obtained from Applied
Biosystems. Real-time PCR amplifications were performed using
TaqMan miRNA Assays (TaqMan MGP probes, FAM dye-
labeled) using Applied Biosystems 7500 Real-Time PCR systems
(Applied Biosystems). The cycle number at which the amplification
plot crosses the threshold was calculated (CT), and the DDCT
method are used to analyze the relative changes in gene expression
and normalized by U6, a non-human ubiquitous miRNA. We
further tested for intra-patient coefficient of variance (CV) by
running PCR from serum collected from a single patient during 8
different RT-PCR runs, and demonstrated the inter assay CV for
the sera was 3.8%, 2.0% and 4.7% for miR-145, miR-155 and U6
SnRNA, respectively. Thus, there was no evidence that uremic
sera altered the CV% and thus we utilized the standard control U6
as an internal control. The expression of angiotensin II type I
receptor (AT1R), myocardin, RUNX-2, Drosha and Dicer was
also analyzed by real time PCR using Taqman gene expression
microRNA and CKD
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assay system (Applied Biosystems) and normalized by beta-actin
[27].
Transfection
To confirm the role of miR-155 on its target gene AT1R in
VSMC, a miR-155 mimic and miR negative control (Applied
Biosystems) were used to promote the function of miR-155.
Briefly, VSMC were seeded in 24-well culture plates until they
were 60-70% confluent. Transfection of 30 nM of miR-155 mimic
or negative control was performed using Lipofectamine RNAi-
MAX reagent (Applied Biosystems) according to the manufactur-
er’s instructions. Non-transfected VSMC was used as control. The
over expression of miR-155 in VSMC was confirmed by real time
PCR of total RNA isolated from miR-155 mimic or negative
control transfected VSMC. The miR-155 target gene AT1R
expression in VSMC was also determined by real time PCR.
Cellular proliferation assay
VSMC were transfected with miR-155 mimic or negative
control and cellular proliferation determined at 48, 72 and 96 hrs
after transfection by Cell Titer 96 Proliferation Assay Kit
(Promega Corporation) according to manufactures’ instruction.
In addition, non-transfected VSMC were also used as control.
Statistical Analysis
All patient variables were described as mean 6 SD. For the
human studies, review of circulating miRNAs, the miR-145 and
miR-155 indicated the results were not normally distributed, and
therefore all of the miRNAs were converted to natural logarithmic
values. T-tests, tests of ANOVA or correlations were calculated to
compare miRNA levels between categorical and continuous
predictors, respectively. Predictors related to miRNA levels at
significance levels of less than 0.1 were included in a multivariate
linear regression models. Gender, race and MDRD eGFR were
forced into the model. Two models were run, the first with all 85
subjects but no LVH, and the second model with only the 59
subjects that had an echocardiogram. For the animal ex vivo data
and in vitro cell culture, comparisons between CKD and normal
animals was done by t-test, and correlations by Pearson Product
Coefficient with a p,0.05 considered significant. (StatView, SAS
Institute, Cary, NC and SigmaPlot, Systat Software Inc, San Jose,
California).
Results
Circulating levels of miR-125b, miR-145 and miR-155 are
decreased in CKD
To determine if patients with CKD have low circulating levels
of miRNA, we analyzed 90 stored blood samples of stage 3 and 4
CKD patients. The characteristics of the patients are shown in
Table 1. By univariate analysis (p,0.1), the level of miR-125b was
correlated with eGFR by MDRD, creatinine, calcium,
1,25(OH)2D, 25(OH)D, and diabetes; miR-145 with eGFR,
diabetes, 25(OH)D, 1,25(OH)2D; and miR-155 with eGFR and
diabetes. There was no relationship of any of these miRNA with
CRP, vascular disease or LVH. However, vascular disease was
associated with increased age (r = 0.21; p = 0.049) and diabetes
and CRP were negatively correlated with presence of LVH
(r = 0.22; p = 0.046). After multivariate adjustment, only eGFR by
MDRD was associated with all three miRNA. For every one ml/
min decrease in eGFR, there were a 0.05, 0.04, and 0.02 unit
decreases in the expression of the miRNA for miR-125b, 145, and
155, respectively. In addition, after adjustment, diabetes continued
to be associated with miR-145 (b=1.69, p = 0.02, 95% CI 0.34,
3.04) but not miR-155. Calcium and vitamin D levels were no
longer significant for miR-125b, miR-145 or miR-155. A model
run only with those subjects who had undergone an echocardio-
gram (n= 63) failed to find any relationship with any of the
miRNAs and LVH.
Given the above results we further examined the effect of the
level of renal function on circulating levels of miR-125b, 145, and
155 by comparing freshly collected serum by real time-PCR from
patients with stage 3–4 CKD, hemodialysis patients and healthy
volunteers. The samples were collected, immediately frozen in
aliquots and analyzed within a one month period, ruling out
degradation with freezer storage. The clinical characteristics are
shown in Table 2 and the results in Figure 1. The circulating levels
of miR-125b (Figure 1A), miR-145 (Figure 1B) and miR-155
(Figure 1C) were all significantly decreased in CKD and
hemodialysis patients compared to those in healthy volunteers.
Because the samples were isolated and PCR run as total RNA, we
further examined the actual concentration of miRNA using an
Agilent Bioanalyzer. For equal amounts of total RNA, the
proportion of miRNA in the samples was not statistically different,
with a trend towards lower proportion in the healthy controls
(Figure 1D). Therefore our low specific miRNA levels are not due
to a decreased proportion of miRNA to total RNA in the
circulation of patients with CKD, nor due to loss from degradation
in the freezer.
The decreased expression of miRNAs in aorta is
associated with changes in target gene expression and
vascular pathology in CKD animals
In order to determine if the miRNA identified in the sera of
patients with CKD had biologic plausibility as potential biomark-
ers, we utilized previously collected thoracic aorta tissue harvested
at 35 weeks of age from CKD and normal animals. There was no
difference in total miRNA concentration between normal and
CKD rats (216661 vs. 221672 ng/ul; Normal vs. CKD). By real
time PCR, the expression of miR-125b, miR-145 and miR-155
were lower in thoracic aorta from CKD compared to that from
Table 1. Characteristics of stage 3–4 CKD patients (n = 90).
Characteristics Mean ± SD
Age [years] 63.0614.4
Gender (Male [n(%)]) 51 (56.6)
Race (Caucasians : African Americans : Others) 51 : 38 : 1
Diabetes mellitus [n(%)] 48 (53.3)
Hypertension [n(%)] 89 (98%)
Vascular disease [n(%)] 33 (36.7)
LVH (no: yes: not done)[n)] 38:25:27
Serum creatinine (mg/dL) 2.060.7
4-parameter MDRD (ml/min/1.73 m2) 35.7611.0
Albumin (g/dl) 3.660.4
Phosphorus (mg/dl) 3.560.7
Calcium (mg/dl) 9.360.4
Intact PTH (pg/ml) 118658
25 hydroxy-vitamin D (ng/ml) 22613
1,25 dihydroxy-vitamin D (pg/ml) 34614
C-reactive protein (mcg/L) 7.468.1
doi:10.1371/journal.pone.0064558.t001
microRNA and CKD
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normal rats (all p,0.01; Figure 2A). As we have previously
reported [25], there was increased calcification in the aorta arch of
the CKD animals compared to the Normal animals (3.360.6 vs.
2.460.8 umol/g tissue, p = 0.04). To determine the relationship
between calcification and down regulation of the miRNA, we
compared the correlation between the magnitude of calcification
and concentration of the miRNA. There were negative correla-
tions of miR-155 with the presence of calcification miR-155 (r = –
0.537, p = 0.04; Figure 2B) and miR-125b and calcification (r = –
0.478, p= 0.07), but no relationship with miR-145. We then
examined downstream gene products that are known to be
regulated by these miRNA. For example, miR-155 directly targets
angiotensin II type I receptor (AT1R) and inhibits AT1R
expression. On the other hand, miR-145 controls VSMC
phenotype by increasing target gene myocardin expression via
inhibition of an intermediary [20,28]. The results found that the
expression of angiotensin II type I receptor (AT1R) was increased
(Figure 2C) and myocardin was decreased (Figure 2D) in CKD
Figure 1. Circulating miRNA levels in controls, CKD patients and hemodialysis patients in freshly isolated samples. Sera were
collected from stage 3–4 CKD patients (n = 10), hemodialysis patients (n = 10) and healthy volunteers (n = 8) and total RNA isolated and real time PCR
performed to determine the expression of circulating levels of miR-125b (A), miR-145 (B) and miR-155 (C) normalized by U6. Total serum miRNA
concentration in the three groups was measured using Agilent Bioanalyzer (D) to demonstrate that the proportion of miRNA to total RNA analyzed is
not the etiology of decreased expression of these specific miRNA. Each sample was assayed in triplicate. Data were expressed as mean 6 SEM. *
p,0.01 compared to healthy volunteers; ** p,0.05 compared to healthy volunteers.
doi:10.1371/journal.pone.0064558.g001
Table 2. Patient characteristics in a cohort of freshly isolated miRNA samples.
Characteristics Healthy (N=8) Stage 3–4 CKD (N=10) Hemodialysis (N=10)
Age 43.4611.5 61.1614.1a 54.8614.0a
Gender (%Male) 25 40 60
Race-Caucasians [N(%)] 5 (62.5) 10 (100) 1 (10)
Race-African Americans [N(%)] 0 (0) 0 (0) 9 (90)a,b
Race-Others [N(%)] 3 (37.5) 0 (0) 0 (0)
DM (%) 0 20 50
HbA1C (%) – 7.8562.05 5.8860.55
ap,0.05 vs. healthy subjects; b p,0.01 vs. healthy subjects.
doi:10.1371/journal.pone.0064558.t002
microRNA and CKD
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animals compared to Normal animals. Furthermore, there was a
strong negative correlation between the miR-155 and expression
of AT1R (r = –.078, p,0.001) and myocardin (r = –0.608,
p = 0.02). However, there was no correlation between AT1R
and RUNX2, or between miR-145 and myocardin. The
expression of RUNX2 was also increased in CKD animals (Figure
2E), with a non-statistical correlation of RUNX2 with miR-125b
(r = –0.47, p = 0.07) and miR-155 (r = –0.45, p = 0.08). In sum-
mary, compared to Normal animals, the CKD animals had
increased calcification in the thoracic aortas, decreased expression
of these vascular miRNAs, and a corresponding increased
expression of RUNX2, AT1R, and decreased expression of
myocardin.
The expression of vascular miRNAs is decreased in VSMC
from CKD compared to normal animals
To determine the effect of CKD on miRNA expression, we
isolated VSMC from the aorta of CKD (Cy/+) rats and their
normal littermates and determined the expression of miR-125b,
miR-145, and miR-155 by real time PCR. Cultured VSMC from
CKD rats had significantly lower expression of miR-125b, miR-
145 and miR-155 compared to that from normal rats (Figure 3A).
We also analyzed miR210, a miRNA known to be upregulated in
acute kidney injury[29,30], demonstrating increased expression in
the VSMC from our CKD animals (Figure 3A), confirming our
findings were not due to uniform miRNA suppression. Further-
more, the total miRNA concentration in these samples from
normal and CKD rats was not different (normal 2536126 pg/ml;
CKD 312691 pg/ml). Cellular miRNA are processed from pro-
miRNA by DROSHA and DICER and thus we determined the
expression of these enzymes in VSMC from CKD compared to
normal rats. The results demonstrated no difference in the
expression of DROSHA/b-actin (normal 1.2760.20; CKD
1.2860.25) and DICER/b-actin (normal = 1.0560.01; CKD
=1.060.06) in VMSC between normal and CKD rats. Similar to
that observed in ex vivo aorta samples, we found a decrease in
myocardin (Figure 3B) and an increase in expression of RUNX-2
(Figure 3C) and AT1R (Figure 3D) in CKD VSMC compared to
normal VSMC.
Effect of overexpression of miR-155 on AT1R expression
and cellular proliferation in VSMC
To confirm a direct relationship between the levels of miR-155
on target gene AT1R expression, VSMC from CKD rats were
transfected with miR-155 mimic or miR negative control for 48
hrs. The results demonstrated that compared to negative control
or non- transfected cells, VSMC transfected with miR-155 mimic
had more than 1000 fold increase in miR-155 expression (Figure
4A). Furthermore, the AT1R expression in VSMC transfected
with miR-155 was significantly decreased compared to that
Figure 2. Decreased expression of miRNAs and downstream genes in thoracic aorta from CKD animals. Thoracic aorta were collected at
35 weeks of age from CKD (n= 8) and normal rats (n = 8) and total RNA was isolated and miRNA expression determined by real time PCR and
normalized by U6. The results demonstrated that there is significantly reduction in expression in miR-125b, miR-145, and in thoracic aorta from CKD
compared to that from normal rats (Figure 2A). Aortic calcification was determined biochemically and results demonstrated that aorta calcification is
increased in CKD rats and the greater the calcification, the lower the miR-155 expression level (r = 0.54, p = 0.04; Figure 2B). Real time PCR was also
performed to determine the expression of several target genes and normalized by b-actin. The results demonstrated that the expression of AT1R
(Figure 2C) and RUNX2 (Figure 2E) is increased whereas myocardin expression is decreased (Figure 2D) in aorta from CKD rats compared to normal
rats, corresponding to known physiologic roles of these vascular miRNA. Data were expressed as mean 6 SEM. * p,0.05, CKD vs. normal.
doi:10.1371/journal.pone.0064558.g002
microRNA and CKD
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negative control or non-transfected VSMC (Figure 4B). The
change in phenotype do a differentiated VSMC is usually
accompanied by increased proliferation [31], we therefore
examined the effect of miR-155 on proliferation in VSMC from
CKD rats. As shown in Figure 5, cellular proliferation were
significantly inhibited at 72 and 96 hrs in VSMC transfected with
miR-155 mimic compared to that in miR negative control or non-
transfected VSMC. These results suggest that miR-155 directly
controls the AT1R expression and regulate cellular proliferation in
VSMC.
Discussion
Patients with CKD are more likely to die of a cardiovascular
event than progress to dialysis[8] and once on dialysis cardiovas-
cular disease is the leading cause of death. We chose to examine
miR-125b, 145 and 155 due to their known role in the regulation
of the VSMC phenotype and the finding that circulating levels are
decreased in patients with coronary artery disease[7]. In the
present study we demonstrate that these vascular miRNAs are
decreased in the serum of patients with CKD and hemodialysis
patients compared to controls and therefore are potential
biomarkers. In a cohort of 90 patients, these decreased levels
were correlated with various abnormalities of CKD, but by
multivariate analysis only loss of kidney function was associated
with decreased circulating levels of all three miRNAs. To
determine the biologic plausibility that these markers may reflect
underlying pathology, we utilized animals and demonstrated that,
compared to normal animals, miR-125b, 145 and 155 are
decreased in the thoracic aorta ex vivo from CKD animals and
cultured VSMC from CKD animals. This model of CKD, the Cy/
+ rat is known to have progressive CKD, increased left ventricular
hypertrophy, arterial calcification and hypertension [25,32] and
thus are phenotypically similar to patients with advanced CKD.
We further examined the mechanism by which these miRNA of
vascular origin are decreased by comparing expression and
regulation in VSMC from CKD rats compared to normal
littermates. The results demonstrated normal processing enzyme
expression of DROSHA and DICER, but decreased expression of
all three vascular miRNA in VSMC from CKD animals compared
to normal animals. Unfortunately we were unable to measure
miRNA in the circulation of rats in which tissue samples existed
due to the methods used to collect the samples. These data support
that the low levels of these miRNA will lead to ‘unregulated’
mRNA and phenotypic vascular changes in the setting of CKD in
our animal model. Such phenotypic switch to a more prolifera-
tive/synthetic state is important in the aberrant remodeling of
CKD and in vascular calcification (Figure 6) [33,34]. Indeed, we
found that downstream mRNA products directly regulated by
these vascular miRNAs were also affected. AT1R is normally
repressed by miR-155, and thus our findings of increased AT1R
expression in the arteries and VSMC of CKD animals may
represent a defect in ‘regulation’ by the low levels of this miRNA.
Using transfection techniques, we confirmed a direct regulatory
effect of miR-155 on AT1R expression in VSMC from CKD rats.
Thus, the known upregulation of AT1R in arteries of patients with
CKD [35] may be a direct result of low levels of the controlling
miRNA-155. Furthermore, we demonstrated that overexpression
Figure 3. The Expression of vascular microRNAs and target genes in VSMCs from normal and CKD rats. Rat VSMC isolated from normal
or CKD rats were cultured in growth media for 4 days and total RNA isolated. Real time PCR was performed to determine the expression of miR-125b,
miR-145, miR-155 and miR-210 and normalized by U6 (A). The expression of myocardin (B), RUNX2 (C) and AT1R (D) was also determined by real time
PCR and normalized by b-actin. Each sample (n = 9 with cells isolated from 3 different normal or CKD animals) was assayed in triplicate. Data were
expressed as mean 6 SEM. * p,0.05, CKD vs. normal.
doi:10.1371/journal.pone.0064558.g003
microRNA and CKD
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e64558
of miR-155 inhibited cell proliferation, confirming that the low
expression of miR-155 may be a causative factor in the
proliferative VSMC state observed in CKD. Although many
significant correlations were observed, the most consistent
observation was with miR-155, whose expression was negatively
correlated with vascular calcification. Taken together, the data
strongly supports a role of miR-155 in the aberrant vascular
remodeling in CKD. Time dependent changes should be
evaluated in the future.
The phenotype of proliferative VSMC has been linked to
hypertension, aberrant response to remodeling after angioplasty,
atherosclerosis and vascular calcification, all common problems in
patients with CKD (Figure 5). Myocardin is a ‘‘master regulator’’
of VSMC phenotype that is upregulated during normal develop-
ment/differentiation, but becomes down regulated when VSMC
turn from a quiescent/contractile state to a proliferative/synthetic
state [36]. Myocardin is normally stimulated by miR-145 [28] and
thus, the low expression of myocardin in our study confirmed the
functional importance of the decreased level of miR-145.
Furthermore, another marker of vascular de-differentiation to an
osteoblast phenotype, RUNX-2, was increased. Thus, in addition
to the effects of miR-155, these results suggest that CKD is
associated with decreased VSMC expression and decreased
circulating levels of several miRNA that control VSMC differen-
tiation and function. The sustained suppression of myocardin
would further lead to a protracted proliferative state of VSMC.
Whether these abnormalities are the cause of vascular disease in
CKD, or due to the presence of vascular disease will need to be
determined from future in vivo studies.
Several other studies support our findings that altered regulation
of these vascular miRNAs are important in the aberrant vascular
disease of CKD. In spontaneously hypertensive rats, the tissue
expression of miR-155 in the aorta is inversely related to blood
pressure [22]. Aortic adventitial fibroblasts (often called myofi-
broblasts) with decreased miR-155 had decreased Angiotensin II
receptor expression [21], a finding that parallels our observations.
Furthermore, overexpression of miR-155 led to differentiation to a
more contractile myofibroblast[21]. MiR-155 inhibits human
angiotensin type 1 receptor (AT1R) expression and the activation
of AT1R receptor mediated signaling cascades in fibroblasts[20].
In addition, one polymorphism in AT1R is likely significant due to
alteration in the miR-155 binding site[37]. Thus, low levels of
circulating miR-155 may lead to activation of AT1R in patients
with CKD, perhaps playing a role in cardiovascular disease and
renal fibrosis [35]. A recent study linked low circulating miR-155
levels with increased risk of sudden cardiac death [38], a leading
cause of death in ESRD patients. miR-155 is also important in
inflammation, and is expressed in both activated B and T cells[18],
perhaps further adding to the pathogenesis of atherosclerosis.
Importantly, not all miRNA were downregulated in the CKD
VSMC as miR-210, previously shown to be upregulated in acute
kidney injury[30], was upregulated in CKD VSMC compared to
normal littermates. Thus, the decreased miR-155 levels in the
arteries of our CKD rats compared to normal littermates are
consistent with the known end organ manifestations of hyperten-
sion, left ventricular hypertrophy and coronary artery and aorta
calcification in these CKD animals[25,32].
VSMC differentiation is tightly controlled during development,
but VSMC maintains plasticity such that de-differentiation occurs
in response to various stimuli in adult life. The regulation of this
de-differentiation is thought to play a major role in pathogenesis of
Figure 4. Overexpression of miR-155 and AT1R expression in
VSMC from CKD rats. Rat VSMC isolated from CKD rats were
transfected with 30 nM of miR-155 mimic or miR negative control for 48
hrs. Non-transfected VSMC (NT) was also used as control. The
overexpression of miR-155 in VSMC was confirmed by real time PCR
(A). The miR-155 target gene AT1R expression in VSMC was also
determined by real time PCR, demonstrating a significant inhibition of
AT1R expression compared to that with negative control or non-
transfected VSMC (B). Data were expressed as mean 6 SEM (n= 3
separate experiments). *p,0.05, miR-155 mimic vs. negative control or
NT.
doi:10.1371/journal.pone.0064558.g004
Figure 5. Upregulation of miR-155 decreases cellular prolifer-
ation in VSMC from CKD rats. Rat VSMC isolated from CKD rats were
transfected with 30 nM of miR-155 mimic or miR negative control. Non-
transfected VSMC (NT) was also used as control. The cellular
proliferation was determined 48, 72 and 96 hrs after transfection using
Cell Titer 96 Proliferation Assay Kit. The results demonstrated that the
transfection of miR-155 mimic significantly inhibited cellular prolifera-
tion at 72 and 96 hrs in VSMC from CKD rats compared to that with
negative control or non-transfected VSMC. Data were expressed as
mean 6 SEM (n = 3 separate experiments). *p,0.05, miR-155 mimic vs.
negative control or NT.
doi:10.1371/journal.pone.0064558.g005
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hypertension, arteriosclerosis and arterial calcification in CKD
[33,34]. Elia et al have shown that the expression of miR-145 is
decreased in mice subjected to aortic constriction and in the ApoE
mouse model of atherosclerosis. Furthermore, they demonstrated
that VSMC from miR-145 null mice are de-differentiated [38].
Importantly, miR-143/145 complex regulates the major pheno-
typic regulator of VSMC myocardin such that decreased
expression converts VSMC to a more proliferative, de-differenti-
ated cell [2,16]. Our in vitro work confirms that in the VSMC
from CKD animals there was downregulation of both miR-145
and myocardin, indicating a more proliferative VSMC [2,16].
Such down regulation of myocardin has also been observed in
human VSMC transfected with siRNA to klotho[39], and with
transfection of the receptor for advanced glycation end-products
(RAGE)[40]. Furthermore, myocardin suppression is downregu-
lated in vascular calcification [39,41], although this may not be as
critical as the upregulation of Runx2 in the VSMC ‘reprogram-
ming’ towards osteochondrogenesis[42]. Since miR-145 normally
increases myocardin, low levels observed in our study in VSMC in
animals with CKD in vitro and in vivo, and in the circulation of
patients with CKD may imply that the normal ‘safeguard’
regulation of myocardin by miR-145 may be impaired. More
work is needed to confirm this hypothesis.
VSMC and osteoblasts differentiate from a common mesen-
chymal precursor, and the de-differentiation of VSMC to
osteoblast like cells is thought to be an initiating factor in the
pathogenesis of arterial calcification [42,43]. We have previously
demonstrated that high phosphorus, and uremic serum without
elevated phosphorus concentrations, induced upregulation of the
osteoblast transcription factor RUNX-2 and mineralization[44].
Furthermore, RUNX2 is also upregulated in vivo in areas of both
intimal and medial calcification of arteries from ESRD pa-
tients[45]. The potential importance of miR-125b in the
regulation of this RUNX2 mediated osteochondrogenic differen-
tiation is supported by a study demonstrating that miR-125b
inhibits the BMP-4 induced differentiation/proliferation of mes-
enchymal stem cells towards an osteoblast phenotype. When the
activity of miR-125b was blocked, there was increased alkaline
phosphatase activity and mineralization, suggesting continued
osteoblast differentiation of these mesenchymal stem cells [23].
When VSMC[24] and adipocytes[40] are induced towards an
osteogenic differentiation pathway through high phosphorus
containing media, there is a decline in miR-125b expression.
Finally, Goettsch et al found that miR-125b was decreased during
calcification of human VSMC [24]. Thus, our findings of down
regulation of miR-125b in both the circulation of patients with
CKD and in arteries and VSMC from CKD rats, and an
upregulation of RUNX2 in arteries/VSMC, suggests that miR-
125b may play a role in preventing this de-differentiation of
VSMC to osteoblast like cells. However, we did not find a
significant correlation between miR-125b and RUNX2 expres-
sion. At this time there is no evidence that RUNX-2 is directly
regulated by miR-125b and thus its effects are likely further
upstream and/or earlier in the differentiation pathway[46].
Indeed, miR-125b has over 7000 possible gene targets (www.
microRNA.org) and is involved in the regulation of NF-kB
(nuclear factor kappa beta)[47] and thus controls differentiation in
cells of multiple origins. Thus, the low levels of miR-125b observed
Figure 6. Hypothesis of the impact of vascular miRNAs on the pathogenesis of cardiovascular disease of CKD. This figure is our
hypothesis of how the miRNAs may affect cardiovascular disease in CKD. During development, normal differentiation of VSMC is controlled in part by
the ‘master’ regulator, myocardin. In adulthood, the majority of VSMC are in a quiescent, synthetic state. During acute insults, these synthetic VSMC
change to a more proliferative state, returning to a quiescent state after the insult. However, in the setting of kidney disease, VSMC appear to stay in a
more proliferative state with corresponding increased expression of AT1R and RUNX2, and decreased myocardin expression. The decreased
expression forces the VSMC to remain in a continual proliferative or de-differentiated state. MiRNAs are known to be important in regulating such
differentiation during development, but the low levels of miR-155, 145, and 125b observed in CKD arteries and VSMC and in the circulation of
patients with CKD in the present study may lead to further propagation of de-differentiated VSMC, potentiating the development of hypertension,
cardiovascular disease and vascular calcification.
doi:10.1371/journal.pone.0064558.g006
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in both the aorta tissue of CKD rats and the sera of CKD patients
may have widespread effects on cell differentiation in multiple
organ systems in CKD.
Despite the potential adverse consequences of low levels of these
vascular miRNAs observed in our study using the rat model, we
were unable to directly link these observations to circulating levels
in the rat as correlating blood samples were not collected in a
manner to allow miRNA analyses. Furthermore, we did not find
an association of circulating levels with the presence of hyperten-
sion, vascular disease (defined broadly as coronary artery disease,
peripheral vascular disease and/or stroke), nor left ventricular
hypertrophy in our human study. This is in contrast to the work of
Fichtlscherer et al who found that miR-145 and 155 were
decreased in non-CKD patients with coronary artery disease with
or without diabetes[7]. The differences may have been due to the
very high prevalence of cardiovascular disease, some of which was
likely undiagnosed, in our cohort. Alternatively, the miRNA levels
in CKD may have been so low due to kidney disease, that this over
shadowed any relationship with cardiovascular disease. It is also
possible that measuring single miRNA may not provide adequate
prediction. Recent studies clearly demonstrate that multiple
miRNAs work in concert to regulate key physiologic function[48].
Thus, microarray methods may be more helpful to demonstrate an
overall picture of alterations in miRNA in CKD patients. In
contrast to the uniform decrease in specific miRNAs we found in
our study, it is important to note that another group of
investigators found that miR-499 was increased 80 fold in dialysis
patients compared to controls; interestingly despite this marked
elevation it appeared that standard hemodialysis substantially
reduced levels (implying a profound increase in production)[49].
Clearly, additional studies linking blood levels to tissue levels in
rats and human blood levels to outcomes prospectively are needed.
Our results are consistent with the study of Neal et al who
demonstrated that miRNA levels similarly correlated inversely
with decreasing GFR, and also found decreasing miR-155 with
decreasing eGFR[50]. They hypothesized that this was due to
degradation by circulating RNAse and performed an ex vivo study
on exosomes from colonic cancer epithelium, demonstrating
increased degradation when incubated with plasma from CKD
patients compared to control plasma[50]. Thus, they did not
evaluate if such degradation occurs in vivo. It is important to point
out that the real time PCR is analyzed on equivalent amounts of
total RNA isolated from blood. For this reason, we individually
measured the actual quantity of miRNA in a randomly selected
group of these samples and found an increase in the proportion of
miRNA to total RNA in the samples from patients with CKD
(Figure 3D) which would suggest there is not degradation in the
circulation. We further tested freshly collected specimens and
found similar results in our analyses. Therefore we believe it is
unlikely that degradation could explain the low levels of the
vascular miRNAs observed in our patients. Our in vitro work
further supports that there is decreased synthesis. More work
needs to be done to characterize the production, degradation and
clearance of miRNA in CKD prior to their use as biomarkers.
In summary, we demonstrated the existence of circulating
microRNAs in CKD and in dialysis patients. The circulating levels
of miR-125b, miR-145 and miR-155 are decreased with
progressive eGFR; the ability to detect such miRNA may offer
hope of a novel cardiovascular biomarker. To determine the
biologic plausibility of these miRNA serving as a future biomarker,
we utilized an animal model and found the expression is decreased
in aorta and cultured VSMC from CKD rats compared to normal
littermates. Furthermore the decrease in and the tissue artery
levels in rats corresponded to altered levels of mRNAs they are
known to regulate, either directly or indirectly, and, at least for
miR-155, correlated with arterial calcification. Upregulation of
miR155 demonstrated a decrease in AT1R expression and
decrease in proliferation, confirming a direct causative role of
the low level of miR155 on VSMC to a more synthetic,
proliferative phenotype. The mechanism for the decreased
expression of these vascular miRNAs in CKD is unclear as we
found normal expression of the miRNA processing enzymes
DROSHA and DICER and no evidence for degradation in the
circulation in CKD. Whether downregulation of these miRNAs
are the cause of, or a consequence of, the widespread vascular
phenotype abnormalities in our patients with CKD remains to be
determined. In conclusion, CKD is associated with decreased
expression of vascular miRNA in rats. Preliminary data in humans
also show low circulating levels. Future studies are required to
determine if the assessment of circulating levels in humans reflect
underlying pathology.
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